Palatin Technologies, Inc. Common Stock
Key Metrics
Market Snapshot
About
Palatin Technologies, Inc. Common Stock (PTN) is a biopharmaceutical company based in Monmouth Junction, New Jersey. Incorporated in 1986, it focuses on developing first-in-class medicines built on molecules that modulate the activity of the melanocortin receptor system in the United States. This receptor system is the scientific foundation that ties together much of the company's research.
The company is advancing several candidates aimed at obesity and related conditions. It is developing an oral small molecule MC4R agonist called PL7737 in preclinical studies, along with long-acting peptide MC4R agonists. It is also studying Bremelanotide given together with Tirzepatide for obesity in a Phase 2 trial, and Bremelanotide co-formulated with a PDE5i to treat erectile dysfunction in patients who do not respond adequately to PDE5i treatment on its own.
Palatin's pipeline extends beyond metabolic and sexual health programs. It is developing PL9643 for dry eye disease and other anti-inflammatory eye conditions, and an oral candidate called PL8177 for the treatment of inflammatory bowel diseases. These programs apply the company's melanocortin science to conditions involving inflammation and the eye, broadening the range of diseases it targets.
As a developer of experimental treatments, Palatin Technologies, Inc. is working to move these candidates through the stages of testing that precede potential approval and wider use. Its concentration on the melanocortin receptor system across obesity, ocular disease, inflammatory bowel disease, and sexual health gives it a defined scientific focus, while its long history since 1986 and its New Jersey base shape its standing as a biopharmaceutical company pursuing first-in-class medicines.